Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Arlington Capital Partners has made a majority growth investment in CBSET to enhance its preclinical research services and support significant capacity expansion.
PRIVATEOct 01, 2025•10 months ago
Round Type
Venture - Series Unknown
LexingtonBiotechnologyHealth Care
Investors
Arlington Capital Partners
Description
Arlington Capital Partners has completed a majority growth investment in Concord Biomedical Sciences and Emerging Technologies, Inc. (CBSET), a Boston-area provider of translational research services. This investment aims to help CBSET scale its research platform through capacity expansion and strategic acquisitions. The partnership is designed to meet the rising demand for specialized preclinical research services in a complex regulatory environment.
Company Information
Company
CBSET
Location
Lexington, Massachusetts, United States
About
CBSET is a leading provider of translational research and product development services for the medical device, pharmaceutical, diagnostic, and biomedical research industries. The company offers a broad range of preclinical research and testing services along with expert regulatory support. Their fully-integrated research platform includes advanced lab facilities and experienced personnel to accelerate the development of medical devices and novel therapeutics.
LexingtonBiotechnologyHealth Care